Camurus AB (publ)
Market Cap
$31.64B
P/E Ratio
-417.76
EPS
$-1.27
Dividend Yield
0.00%
52-Week Range
$197.70 — $596.00
Volume
2.26K
Avg Volume
24.53K
Beta
0.45
Get alerted when 0RD1.L hits your target price.
Free — enter your email to get started
P/E (TTM)
-417.76
Forward P/E
29.29
PEG Ratio
-7.09
P/S (TTM)
14.07
P/B (TTM)
7.54
P/FCF
—
EV/EBITDA
—
EV/Sales
—
ROE (TTM)
0.19%
ROA (TTM)
0.16%
ROIC
—
Gross Margin
0.93%
Operating Margin
0.39%
Net Margin
—
Debt/Equity
0.03
Current Ratio
12.09
EPS Growth (YoY)
—
Revenue Growth (YoY)
—
EPS Growth (3Y)
+2.75%
EPS Growth (5Y)
+1.85%
Sales Growth (3Y)
+0.49%
Sales Growth (5Y)
+0.89%
EPS Est (This Year)
$18.11
EPS Est (Next Year)
$30.25
Dividend Yield
—
Annual Dividend
—
Payout Ratio
—
Frequency
—
Ex-Dividend Date
—
Cash/Share
$62.24
Institutional %
—
Inst. Net Change
—
Insider Net Shares (90d)
—
Outstanding Shares
59.61M
Float
35.10M
Free Float %
58.89%
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Country
SE
Exchange
LSE
IPO Date
2016-05-03
Employees
238
CEO
Fredrik Tiberg
Index Membership
—
Website
https://www.camurus.com
Camurus AB (publ) (0RD1.L) is a healthcare company in the medical - pharmaceuticals industry listed on the LSE. With a market capitalization of $31.64B, a P/E ratio of -417.76, 0RD1.L is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare 0RD1.L against other stocks using dozens of fundamental and technical filters.
0QZU.L
Vertex Pharmaceuticals Incorporated
$428.00
+1.25%
$110.00B
0R2M.L
Regeneron Pharmaceuticals, Inc.
$685.53
+1.37%
$74.06B
0M3Q.L
Zoetis Inc.
$115.60
+1.72%
$55.54B
0J2O.L
Halozyme Therapeutics, Inc.
$64.11
+1.60%
$7.57B
0HD2.L
Alnylam Pharmaceuticals, Inc.
$319.08
+7.54%
$42.32B
0JAV.L
Insmed Incorporated
$136.55
+1.81%
$29.44B
Camurus AB (publ) (0RD1.L) has a trailing twelve-month (TTM) P/E ratio of -417.76. This is below the market average, which may suggest the stock is undervalued or has lower growth expectations. The P/E ratio measures how much investors are willing to pay per dollar of earnings.
No, Camurus AB (publ) (0RD1.L) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.
Camurus AB (publ) (0RD1.L) has a market capitalization of $31.64 billion, classifying it as a large-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.